<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing.dtd" [ ]>
<sequence-cwu id="SEQLST-1">
<publication-reference>
<document-id>
<country>US</country>
<doc-number>20070003563</doc-number>
<kind>A1</kind>
<date>20070104</date>
</document-id>
</publication-reference>
<number>1</number>
<sequence-list-new-rules>
<s100>
<s160>21 </s160>
</s100>
<s200>
<s210>1 </s210>
<s211>9 </s211>
<s212>PRT </s212>
<s213>Homo sapien </s213>
</s200>
<s400> 1 
Lys Ala Ser Glu Lys Ile Phe Tyr Val 
 1               5 
</s400>
<s200>
<s210>2 </s210>
<s211>9 </s211>
<s212>PRT </s212>
<s213>Homo sapien </s213>
</s200>
<s400> 2 
Ser Leu Leu Met Trp Ile Thr Gln Cys 
 1               5 
</s400>
<s200>
<s210>3 </s210>
<s211>9 </s211>
<s212>PRT </s212>
<s213>Homo sapien </s213>
</s200>
<s400> 3 
Ser Leu Leu Gln His Leu Ile Gly Leu 
 1               5 
</s400>
<s200>
<s210>4 </s210>
<s211>10 </s211>
<s212>PRT </s212>
<s213>Homo sapien </s213>
</s200>
<s400> 4 
Gly Leu Pro Ser Ile Pro Val His Pro Ile 
 1               5                  10 
</s400>
<s200>
<s210>5 </s210>
<s211>9 </s211>
<s212>PRT </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Man made peptide </s223>
</s220>
</s200>
<s400> 5 
Lys Val Ser Glu Lys Ile Phe Tyr Val 
 1               5 
</s400>
<s200>
<s210>6 </s210>
<s211>9 </s211>
<s212>PRT </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Analog of NY-ESO-1, amino acids 157-165 
</s223>
</s220>
<s220>
<s221>VARIANT </s221>
<s222>2 
</s222>
<s223>Xaa = Norvaline </s223>
</s220>
</s200>
<s400> 6 
Ser Xaa Leu Met Trp Ile Thr Gln Val 
 1               5 
</s400>
<s200>
<s210>7 </s210>
<s211>9 </s211>
<s212>PRT </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Analog of PRAME, amino acids 425-433 
</s223>
</s220>
<s220>
<s221>VARIANT </s221>
<s222>2 
</s222>
<s223>Xaa = Norvaline 
</s223>
</s220>
<s220>
<s221>VARIANT </s221>
<s222>9 
</s222>
<s223>Xaa = Norleucine </s223>
</s220>
</s200>
<s400> 7 
Ser Xaa Leu Gln His Leu Ile Gly Xaa 
 1               5 
</s400>
<s200>
<s210>8 </s210>
<s211>10 </s211>
<s212>PRT </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Man made peptide </s223>
</s220>
</s200>
<s400> 8 
Gly Leu Pro Ser Ile Pro Val His Pro Val 
 1               5                  10 
</s400>
<s200>
<s210>9 </s210>
<s211>10 </s211>
<s212>PRT </s212>
<s213>Homo sapien </s213>
</s200>
<s400> 9 
Glu Leu Ala Gly Ile Gly Ile Leu Thr Val 
 1               5                  10 
</s400>
<s200>
<s210>10 </s210>
<s211>9 </s211>
<s212>PRT </s212>
<s213>Homo sapien </s213>
</s200>
<s400> 10 
Tyr Met Asp Gly Thr Met Ser Gln Val 
 1               5 
</s400>
<s200>
<s210>11 </s210>
<s211>10 </s211>
<s212>PRT </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Analog of Melan-A, amino acids 26-35 
</s223>
</s220>
<s220>
<s221>VARIANT </s221>
<s222>2 
</s222>
<s223>Xaa = Norvaline </s223>
</s220>
</s200>
<s400> 11 
Glu Xaa Ala Gly Ile Gly Ile Leu Thr Val 
 1               5                  10 
</s400>
<s200>
<s210>12 </s210>
<s211>9 </s211>
<s212>PRT </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Analog of tyrosinase, amino acids 369-377 
</s223>
</s220>
<s220>
<s221>VARIANT </s221>
<s222>9 
</s222>
<s223>Xaa = Norvaline </s223>
</s220>
</s200>
<s400> 12 
Tyr Met Asp Gly Thr Met Ser Gln Xaa 
 1               5 
</s400>
<s200>
<s210>13 </s210>
<s211>29 </s211>
<s212>PRT </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Man made peptide </s223>
</s220>
</s200>
<s400> 13 
Ile Lys Ala Ser Glu Lys Ile Phe Tyr Val Ser Leu Leu Met Trp Ile 
 1               5                  10                  15 
Thr Gln Cys Lys Ala Ser Glu Lys Ile Phe Tyr Val Lys 
            20                  25 
</s400>
<s200>
<s210>14 </s210>
<s211>62 </s211>
<s212>PRT </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Man made peptide </s223>
</s220>
</s200>
<s400> 14 
Lys Arg Ser Leu Leu Gln His Leu Ile Gly Leu Gly Asp Ala Ala Tyr 
 1               5                  10                  15 
Ser Leu Leu Gln His Leu Ile Gly Leu Ile Ser Pro Glu Lys Glu Glu 
            20                  25                  30 
Gln Tyr Ile Ala Ser Leu Leu Gln His Leu Ile Gly Leu Lys Arg Pro 
        35                  40                  45 
Ser Ile Lys Arg Gly Leu Pro Ser Ile Pro Val His Pro Val 
    50                  55                  60 
</s400>
<s200>
<s210>15 </s210>
<s211>28 </s211>
<s212>PRT </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Man made peptide </s223>
</s220>
</s200>
<s400> 15 
Met Leu Leu Ala Val Leu Tyr Cys Leu Glu Leu Ala Gly Ile Gly Ile 
 1               5                  10                  15 
Leu Thr Val Tyr Met Asp Gly Thr Met Ser Gln Val 
            20                  25 
</s400>
<s200>
<s210>16 </s210>
<s211>179 </s211>
<s212>PRT </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Man made peptide </s223>
</s220>
</s200>
<s400> 16 
Met Ser Leu Leu Met Trp Ile Thr Gln Cys Lys Ala Ser Glu Lys Ile 
 1               5                  10                  15 
Phe Tyr Val Gly Leu Pro Ser Ile Pro Val His Pro Ile Gly Leu Pro 
            20                  25                  30 
Ser Ile Pro Val His Pro Ile Lys Ala Ser Glu Lys Ile Phe Tyr Val 
        35                  40                  45 
Ser Leu Leu Met Trp Ile Thr Gln Cys Lys Ala Ser Glu Lys Ile Phe 
    50                  55                  60 
Tyr Val Lys Ala Ser Glu Lys Ile Phe Tyr Val Arg Cys Gly Ala Arg 
65                  70                  75                  80 
Gly Pro Glu Ser Arg Leu Leu Glu Phe Tyr Leu Ala Met Pro Phe Ala 
                85                  90                  95 
Thr Pro Met Glu Ala Glu Leu Ala Arg Arg Ser Leu Ala Gln Asp Ala 
            100                 105                 110 
Pro Pro Leu Pro Val Pro Gly Val Leu Leu Lys Glu Phe Thr Val Ser 
        115                 120                 125 
Gly Asn Ile Leu Thr Ile Arg Leu Thr Ala Ala Asp His Arg Gln Leu 
    130                 135                 140 
Gln Leu Ser Ile Ser Ser Cys Leu Gln Gln Leu Ser Leu Leu Met Trp 
145                 150                 155                 160 
Ile Thr Gln Cys Phe Leu Pro Val Phe Leu Ala Gln Pro Pro Ser Gly 
                165                 170                 175 
Gln Arg Arg 
</s400>
<s200>
<s210>17 </s210>
<s211>275 </s211>
<s212>PRT </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Man made peptide </s223>
</s220>
</s200>
<s400> 17 
Met Asn Leu Leu His Glu Thr Asp Ser Ala Val Ala Thr Ala Arg Arg 
 1               5                  10                  15 
Pro Arg Trp Leu Cys Ala Gly Ala Leu Val Leu Ala Gly Gly Phe Phe 
            20                  25                  30 
Leu Leu Gly Phe Leu Phe Gly Trp Phe Ile Lys Ser Ala Gln Leu Ala 
        35                  40                  45 
Gly Ala Lys Gly Val Ile Leu Tyr Ser Asp Pro Ala Asp Tyr Phe Ala 
    50                  55                  60 
Pro Gly Val Lys Ser Tyr Pro Asp Gly Trp Asn Leu Pro Gly Gly Gly 
65                  70                  75                  80 
Val Gln Arg Gly Asn Ile Leu Asn Leu Asn Gly Ala Gly Asp Pro Leu 
                85                  90                  95 
Thr Pro Gly Tyr Pro Ala Asn Glu Tyr Ala Tyr Arg Arg Gly Ile Ala 
            100                 105                 110 
Glu Ala Val Gly Leu Pro Ser Ile Pro Val His Pro Ile Ala Leu Gln 
        115                 120                 125 
Ser Leu Leu Gln His Leu Ile Gly Leu Ser Asn Leu Thr His Val Leu 
    130                 135                 140 
Tyr Pro Val Pro Leu Glu Ser Tyr Glu Asp Ile His Gly Thr Leu His 
145                 150                 155                 160 
Leu Glu Arg Leu Ala Tyr Leu His Ala Arg Leu Arg Glu Leu Leu Cys 
                165                 170                 175 
Glu Leu Gly Arg Pro Ser Met Val Trp Leu Ser Ala Asn Pro Cys Pro 
            180                 185                 190 
His Cys Gly Asp Arg Thr Phe Tyr Asp Pro Glu Pro Ile Leu Cys Pro 
        195                 200                 205 
Cys Phe Met Pro Asn Lys Arg Ser Leu Leu Gln His Leu Ile Gly Leu 
    210                 215                 220 
Gly Asp Ala Ala Tyr Ser Leu Leu Gln His Leu Ile Gly Leu Ile Ser 
225                 230                 235                 240 
Pro Glu Lys Glu Glu Gln Tyr Ile Ala Ser Leu Leu Gln His Leu Ile 
                245                 250                 255 
Gly Leu Lys Arg Pro Ser Ile Lys Arg Gly Leu Pro Ser Ile Pro Val 
            260                 265                 270 
His Pro Val 
        275 
</s400>
<s200>
<s210>18 </s210>
<s211>94 </s211>
<s212>PRT </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Man made peptide </s223>
</s220>
</s200>
<s400> 18 
Met Leu Leu Ala Val Leu Tyr Cys Leu Glu Leu Ala Gly Ile Gly Ile 
 1               5                  10                  15 
Leu Thr Val Tyr Met Asp Gly Thr Met Ser Gln Val Gly Ile Leu Thr 
            20                  25                  30 
Val Ile Leu Gly Val Leu Leu Leu Ile Gly Cys Trp Tyr Cys Arg Arg 
        35                  40                  45 
Arg Asn Gly Tyr Arg Ala Leu Met Asp Lys Ser Leu His Val Gly Thr 
    50                  55                  60 
Gln Cys Ala Leu Thr Arg Arg Cys Pro Gln Glu Gly Phe Asp His Arg 
65                  70                  75                  80 
Asp Ser Lys Val Ser Leu Gln Glu Lys Asn Cys Glu Pro Val 
                85                  90 
</s400>
<s200>
<s210>19 </s210>
<s211>3315 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Plasmid </s223>
</s220>
</s200>
<s400> 19 
atatacgcgt tgacattgat tattgactag ttattaatag taatcaatta cggggtcatt     60 
agttcatagc ccatatatgg agttccgcgt tacataactt acggtaaatg gcccgcctgg    120 
ctgaccgccc aacgaccccc gcccattgac gtcaataatg acgtatgttc ccatagtaac    180 
gccaataggg actttccatt gacgtcaatg ggtggagtat ttacggtaaa ctgcccactt    240 
ggcagtacat caagtgtatc atatgccaag tacgccccct attgacgtca atgacggtaa    300 
atggcccgcc tggcattatg cccagtacat gaccttatgg gactttccta cttggcagta    360 
catctacgta ttagtcatcg ctattaccat ggtgatgcgg ttttggcagt acatcaatgg    420 
gcgtggatag cggtttgact cacggggatt tccaagtctc caccccattg acgtcaatgg    480 
gagtttgttt tggcaccaaa atcaacggga ctttccaaaa tgtcgtaaca actccgcccc    540 
attgacgcaa atgggcggta ggcgtgtacg gtgggaggtc tatataagca gagctctctg    600 
gctaactaga gaacccactg cttactggct tatcgaaatt aatacgactc actataggga    660 
gacccaagct ggctagcgtt taaacttaag ccaccatgtt actagctgtt ttgtactgcc    720 
tggaactagc agggatcggc atattgacag tgtatatgga tggaacaatg tcccaggtag    780 
gaattctgac agtgatcctg ggagtcttac tgctcatcgg ctgttggtat tgtagaagac    840 
gaaatggata cagagccttg atggataaaa gtcttcatgt tggcactcaa tgtgccttaa    900 
caagaagatg cccacaagaa gggtttgatc atcgggacag caaagtgtct cttcaagaga    960 
aaaactgtga acctgtgtag tgagcggccg ctcgagtcta gagggcccgt ttaaacccgc   1020 
tgatcagcct cgactgtgcc ttctagttgc cagccatctg ttgtttgccc ctcccccgtg   1080 
ccttccttga ccctggaagg tgccactccc actgtccttt cctaataaaa tgaggaaatt   1140 
gcatcgcatt gtctgagtag gtgtcattct attctggggg gtggggtggg gcaggacagc   1200 
aagggggagg attgggaaga caatagcagg catgctgggg atgcggtggg ctctatggct   1260 
tctactgggc ggttttatgg acagcaagcg aaccggaatt gccagctggg gcgccctctg   1320 
gtaaggttgg gaagccctgc aaagtaaact ggatggcttt cttgccgcca aggatctgat   1380 
ggcgcagggg atcaagctct gatcaagaga caggatgagg atcgtttcgc atgattgaac   1440 
aagatggatt gcacgcaggt tctccggccg cttgggtgga gaggctattc ggctatgact   1500 
gggcacaaca gacaatcggc tgctctgatg ccgccgtgtt ccggctgtca gcgcaggggc   1560 
gcccggttct ttttgtcaag accgacctgt ccggtgccct gaatgaactg caagacgagg   1620 
cagcgcggct atcgtggctg gccacgacgg gcgttccttg cgcagctgtg ctcgacgttg   1680 
tcactgaagc gggaagggac tggctgctat tgggcgaagt gccggggcag gatctcctgt   1740 
catctcacct tgctcctgcc gagaaagtat ccatcatggc tgatgcaatg cggcggctgc   1800 
atacgcttga tccggctacc tgcccattcg accaccaagc gaaacatcgc atcgagcgag   1860 
cacgtactcg gatggaagcc ggtcttgtcg atcaggatga tctggacgaa gagcatcagg   1920 
ggctcgcgcc agccgaactg ttcgccaggc tcaaggcgag catgcccgac ggcgaggatc   1980 
tcgtcgtgac ccatggcgat gcctgcttgc cgaatatcat ggtggaaaat ggccgctttt   2040 
ctggattcat cgactgtggc cggctgggtg tggcggaccg ctatcaggac atagcgttgg   2100 
ctacccgtga tattgctgaa gagcttggcg gcgaatgggc tgaccgcttc ctcgtgcttt   2160 
acggtatcgc cgctcccgat tcgcagcgca tcgccttcta tcgccttctt gacgagttct   2220 
tctgaattat taacgcttac aatttcctga tgcggtattt tctccttacg catctgtgcg   2280 
gtatttcaca ccgcatcagg tggcactttt cggggaaatg tgcgcggaac ccctatttgt   2340 
ttatttttct aaatacattc aaatatgtat ccgctcatga gacaataacc ctgataaatg   2400 
cttcaataat agcacgtgct aaaacttcat ttttaattta aaaggatcta ggtgaagatc   2460 
ctttttgata atctccggaa gagtcaagaa catgtgagca aaaggccagc aaaaggccag   2520 
gaaccgtaaa aaggccgcgt tgctggcgtt tttccatagg ctccgccccc ctgacgagca   2580 
tcacaaaaat cgacgctcaa gtcagaggtg gcgaaacccg acaggactat aaagatacca   2640 
ggcgtttccc cctggaagct ccctcgtgcg ctctcctgtt ccgaccctgc cgcttaccgg   2700 
atacctgtcc gcctttctcc cttcgggaag cgtggcgctt tctcatagct cacgctgtag   2760 
gtatctcagt tcggtgtagg tcgttcgctc caagctgggc tgtgtgcacg aaccccccgt   2820 
tcagcccgac cgctgcgcct tatccggtaa ctatcgtctt gagtccaacc cggtaagaca   2880 
cgacttatcg ccactggcag cagccactgg taacaggatt agcagagcga ggtatgtagg   2940 
cggtgctaca gagttcttga agtggtggcc taactacggc tacactagaa gaacagtatt   3000 
tggtatctgc gctctgctga agccagttac cttcggaaaa agagttggta gctcttgatc   3060 
cggcaaacaa accaccgctg gtagcggtgg tttttttgtt tgcaagcagc agattacgcg   3120 
cagaaaaaaa ggatctcaag aagatccttt gatcttttct acggggtctg acgctcagtg   3180 
gaacgaaaac tcacgttaag ggattttggt ccggccggaa acgtttggtt gctgactaat   3240 
tgagatgcat gctttgcata cttctgcctg ctggggagcc tggggacttt ccacacctcg   3300 
cgatgtacgg gccag                                                    3315 
</s400>
<s200>
<s210>20 </s210>
<s211>3596 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Plasmid </s223>
</s220>
</s200>
<s400> 20 
gttgacattg attattgact agttattaat agtaatcaat tacggggtca ttagttcata     60 
gcccatatat ggagttccgc gttacataac ttacggtaaa tggcccgcct ggctgaccgc    120 
ccaacgaccc ccgcccattg acgtcaataa tgacgtatgt tcccatagta acgccaatag    180 
ggactttcca ttgacgtcaa tgggtggagt atttacggta aactgcccac ttggcagtac    240 
atcaagtgta tcatatgcca agtacgcccc ctattgacgt caatgacggt aaatggcccg    300 
cctggcatta tgcccagtac atgaccttat gggactttcc tacttggcag tacatctacg    360 
tattagtcat cgctattacc atggtgatgc ggttttggca gtacatcaat gggcgtggat    420 
agcggtttga ctcacgggga tttccaagtc tccaccccat tgacgtcaat gggagtttgt    480 
tttggcacca aaatcaacgg gactttccaa aatgtcgtaa caactccgcc ccattgacgc    540 
aaatgggcgg taggcgtgta cggtgggagg tctatataag cagagctctc tggctaacta    600 
gagaacccac tgcttactgg cttatcgaaa ttaatacgac tcactatagg gagacccaag    660 
ctggctagcg tttaaactta agccaccatg tccctgttga tgtggatcac gcagtgcaaa    720 
gcttcggaga aaatcttcta tgtgggtctt ccaagtattc ctgttcatcc aattggtctt    780 
ccaagtattc ctgttcatcc aattaaagct tcggagaaaa tcttctatgt gtccctgttg    840 
atgtggatca cgcagtgcaa agcttcggag aaaatcttct atgtgaaagc ttcggagaaa    900 
atcttctacg tacggtgcgg tgccaggggg ccggagagcc gcctgcttga gttctacctc    960 
gccatgcctt tcgcgacacc catggaagca gagctggccc gcaggagcct ggcccaggat   1020 
gccccaccgc ttcccgtgcc aggggtgctt ctgaaggagt tcactgtgtc cggcaacata   1080 
ctgactatcc gactgactgc tgcagaccac cgccaactgc agctctccat cagctcctgt   1140 
ctccagcagc tttccctgtt gatgtggatc acgcagtgct ttctgcccgt gtttttggct   1200 
cagcctccct cagggcagag gcgctagtga gaattctgca gatatccatc acactggcgg   1260 
ccgctcgagt ctagagggcc cgtttaaacc cgctgatcag cctcgactgt gccttctagt   1320 
tgccagccat ctgttgtttg cccctccccc gtgccttcct tgaccctgga aggtgccact   1380 
cccactgtcc tttcctaata aaatgaggaa attgcatcgc attgtctgag taggtgtcat   1440 
tctattctgg ggggtggggt ggggcaggac agcaaggggg aggattggga agacaatagc   1500 
aggcatgctg gggatgcggt gggctctatg gcttctactg ggcggtttta tggacagcaa   1560 
gcgaaccgga attgccagct ggggcgccct ctggtaaggt tgggaagccc tgcaaagtaa   1620 
actggatggc tttcttgccg ccaaggatct gatggcgcag gggatcaagc tctgatcaag   1680 
agacaggatg aggatcgttt cgcatgattg aacaagatgg attgcacgca ggttctccgg   1740 
ccgcttgggt ggagaggcta ttcggctatg actgggcaca acagacaatc ggctgctctg   1800 
atgccgccgt gttccggctg tcagcgcagg ggcgcccggt tctttttgtc aagaccgacc   1860 
tgtccggtgc cctgaatgaa ctgcaagacg aggcagcgcg gctatcgtgg ctggccacga   1920 
cgggcgttcc ttgcgcagct gtgctcgacg ttgtcactga agcgggaagg gactggctgc   1980 
tattgggcga agtgccgggg caggatctcc tgtcatctca ccttgctcct gccgagaaag   2040 
tatccatcat ggctgatgca atgcggcggc tgcatacgct tgatccggct acctgcccat   2100 
tcgaccacca agcgaaacat cgcatcgagc gagcacgtac tcggatggaa gccggtcttg   2160 
tcgatcagga tgatctggac gaagagcatc aggggctcgc gccagccgaa ctgttcgcca   2220 
ggctcaaggc gagcatgccc gacggcgagg atctcgtcgt gacccatggc gatgcctgct   2280 
tgccgaatat catggtggaa aatggccgct tttctggatt catcgactgt ggccggctgg   2340 
gtgtggcgga ccgctatcag gacatagcgt tggctacccg tgatattgct gaagagcttg   2400 
gcggcgaatg ggctgaccgc ttcctcgtgc tttacggtat cgccgctccc gattcgcagc   2460 
gcatcgcctt ctatcgcctt cttgacgagt tcttctgaat tattaacgct tacaatttcc   2520 
tgatgcggta ttttctcctt acgcatctgt gcggtatttc acaccgcatc aggtggcact   2580 
tttcggggaa atgtgcgcgg aacccctatt tgtttatttt tctaaataca ttcaaatatg   2640 
tatccgctca tgagacaata accctgataa atgcttcaat aatagcacgt gctaaaactt   2700 
catttttaat ttaaaaggat ctaggtgaag atcctttttg ataatctccg gaagagtcaa   2760 
gaacatgtga gcaaaaggcc agcaaaaggc caggaaccgt aaaaaggccg cgttgctggc   2820 
gtttttccat aggctccgcc cccctgacga gcatcacaaa aatcgacgct caagtcagag   2880 
gtggcgaaac ccgacaggac tataaagata ccaggcgttt ccccctggaa gctccctcgt   2940 
gcgctctcct gttccgaccc tgccgcttac cggatacctg tccgcctttc tcccttcggg   3000 
aagcgtggcg ctttctcata gctcacgctg taggtatctc agttcggtgt aggtcgttcg   3060 
ctccaagctg ggctgtgtgc acgaaccccc cgttcagccc gaccgctgcg ccttatccgg   3120 
taactatcgt cttgagtcca acccggtaag acacgactta tcgccactgg cagcagccac   3180 
tggtaacagg attagcagag cgaggtatgt aggcggtgct acagagttct tgaagtggtg   3240 
gcctaactac ggctacacta gaagaacagt atttggtatc tgcgctctgc tgaagccagt   3300 
taccttcgga aaaagagttg gtagctcttg atccggcaaa caaaccaccg ctggtagcgg   3360 
tggttttttt gtttgcaagc agcagattac gcgcagaaaa aaaggatctc aagaagatcc   3420 
tttgatcttt tctacggggt ctgacgctca gtggaacgaa aactcacgtt aagggatttt   3480 
ggtccggccg gaaacgtttg gttgctgact aattgagatg catgctttgc atacttctgc   3540 
ctgctgggga gcctggggac tttccacacc tcgcgatgta cgggccagat atacgc       3596 
</s400>
<s200>
<s210>21 </s210>
<s211>3884 </s211>
<s212>DNA </s212>
<s213>Artificial Sequence </s213>
<s220>
<s223>Plasmid </s223>
</s220>
</s200>
<s400> 21 
cgttgacatt gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat     60 
agcccatata tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg    120 
cccaacgacc cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata    180 
gggactttcc attgacgtca atgggtggag tatttacggt aaactgccca cttggcagta    240 
catcaagtgt atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc    300 
gcctggcatt atgcccagta catgacctta tgggactttc ctacttggca gtacatctac    360 
gtattagtca tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga    420 
tagcggtttg actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg    480 
ttttggcacc aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg    540 
caaatgggcg gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact    600 
agagaaccca ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa    660 
gctggctagc gtttaaactt aagccaccat gaatctcctt cacgaaaccg actcggctgt    720 
ggccaccgcg cgccgcccgc gctggctgtg cgctggggcg ctggtgctgg cgggtggctt    780 
ctttctcctc ggcttcctct tcgggtggtt tataaaaagc gctcagctgg caggggccaa    840 
aggagtcatt ctctactccg accctgctga ctactttgct cctggggtga agtcctatcc    900 
agatggttgg aatcttcctg gaggtggtgt ccagcgtgga aatatcctaa atctgaatgg    960 
tgcaggagac cctctcacac caggttaccc agcaaatgaa tatgcttata ggcgtggaat   1020 
tgcagaggct gttggtcttc caagtattcc tgttcatcct attgccctgc agagtctctt   1080 
gcagcacctc atcgggctga gcaatctgac ccacgtgctg tatcctgtcc ccctggagag   1140 
ttatgaggac atccatggta ccctccacct ggagaggctt gcctatctgc atgccaggct   1200 
cagggagttg ctgtgtgagt tggggcggcc cagcatggtc tggcttagtg ccaacccctg   1260 
tcctcactgt ggggacagaa ccttctatga cccggagccc atcctgtgcc cctgtttcat   1320 
gcctaacaag cgatcgctcc tgcaacacct catcgggctg ggggacgccg cctacagtct   1380 
cctgcaacac ctcatcgggc tgatttcccc ggagaaggaa gagcagtata tcgccagtct   1440 
cctgcaacac ctcatcgggc tgaagaggcc aagtattaag aggggtcttc caagtattcc   1500 
tgttcatcca gtttagtgag aattctgcag atatccatca cactggcggc cgctcgagtc   1560 
tagagggccc gtttaaaccc gctgatcagc ctcgactgtg ccttctagtt gccagccatc   1620 
tgttgtttgc ccctcccccg tgccttcctt gaccctggaa ggtgccactc ccactgtcct   1680 
ttcctaataa aatgaggaaa ttgcatcgca ttgtctgagt aggtgtcatt ctattctggg   1740 
gggtggggtg gggcaggaca gcaaggggga ggattgggaa gacaatagca ggcatgctgg   1800 
ggatgcggtg ggctctatgg cttctactgg gcggttttat ggacagcaag cgaaccggaa   1860 
ttgccagctg gggcgccctc tggtaaggtt gggaagccct gcaaagtaaa ctggatggct   1920 
ttcttgccgc caaggatctg atggcgcagg ggatcaagct ctgatcaaga gacaggatga   1980 
ggatcgtttc gcatgattga acaagatgga ttgcacgcag gttctccggc cgcttgggtg   2040 
gagaggctat tcggctatga ctgggcacaa cagacaatcg gctgctctga tgccgccgtg   2100 
ttccggctgt cagcgcaggg gcgcccggtt ctttttgtca agaccgacct gtccggtgcc   2160 
ctgaatgaac tgcaagacga ggcagcgcgg ctatcgtggc tggccacgac gggcgttcct   2220 
tgcgcagctg tgctcgacgt tgtcactgaa gcgggaaggg actggctgct attgggcgaa   2280 
gtgccggggc aggatctcct gtcatctcac cttgctcctg ccgagaaagt atccatcatg   2340 
gctgatgcaa tgcggcggct gcatacgctt gatccggcta cctgcccatt cgaccaccaa   2400 
gcgaaacatc gcatcgagcg agcacgtact cggatggaag ccggtcttgt cgatcaggat   2460 
gatctggacg aagagcatca ggggctcgcg ccagccgaac tgttcgccag gctcaaggcg   2520 
agcatgcccg acggcgagga tctcgtcgtg acccatggcg atgcctgctt gccgaatatc   2580 
atggtggaaa atggccgctt ttctggattc atcgactgtg gccggctggg tgtggcggac   2640 
cgctatcagg acatagcgtt ggctacccgt gatattgctg aagagcttgg cggcgaatgg   2700 
gctgaccgct tcctcgtgct ttacggtatc gccgctcccg attcgcagcg catcgccttc   2760 
tatcgccttc ttgacgagtt cttctgaatt attaacgctt acaatttcct gatgcggtat   2820 
tttctcctta cgcatctgtg cggtatttca caccgcatca ggtggcactt ttcggggaaa   2880 
tgtgcgcgga acccctattt gtttattttt ctaaatacat tcaaatatgt atccgctcat   2940 
gagacaataa ccctgataaa tgcttcaata atagcacgtg ctaaaacttc atttttaatt   3000 
taaaaggatc taggtgaaga tcctttttga taatctccgg aagagtcaag aacatgtgag   3060 
caaaaggcca gcaaaaggcc aggaaccgta aaaaggccgc gttgctggcg tttttccata   3120 
ggctccgccc ccctgacgag catcacaaaa atcgacgctc aagtcagagg tggcgaaacc   3180 
cgacaggact ataaagatac caggcgtttc cccctggaag ctccctcgtg cgctctcctg   3240 
ttccgaccct gccgcttacc ggatacctgt ccgcctttct cccttcggga agcgtggcgc   3300 
tttctcatag ctcacgctgt aggtatctca gttcggtgta ggtcgttcgc tccaagctgg   3360 
gctgtgtgca cgaacccccc gttcagcccg accgctgcgc cttatccggt aactatcgtc   3420 
ttgagtccaa cccggtaaga cacgacttat cgccactggc agcagccact ggtaacagga   3480 
ttagcagagc gaggtatgta ggcggtgcta cagagttctt gaagtggtgg cctaactacg   3540 
gctacactag aagaacagta tttggtatct gcgctctgct gaagccagtt accttcggaa   3600 
aaagagttgg tagctcttga tccggcaaac aaaccaccgc tggtagcggt ggtttttttg   3660 
tttgcaagca gcagattacg cgcagaaaaa aaggatctca agaagatcct ttgatctttt   3720 
ctacggggtc tgacgctcag tggaacgaaa actcacgtta agggattttg gtccggccgg   3780 
aaacgtttgg ttgctgacta attgagatgc atgctttgca tacttctgcc tgctggggag   3840 
cctggggact ttccacacct cgcgatgtac gggccagata tacg                    3884
</s400>
</sequence-list-new-rules>
</sequence-cwu>
<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE us-patent-application SYSTEM "us-patent-application-v42-2006-08-23.dtd" [ ]>
<us-patent-application lang="EN" dtd-version="v4.2 2006-08-23" file="US20070003564A1-20070104.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20061221" date-publ="20070104">
<us-bibliographic-data-application lang="EN" country="US">
<publication-reference>
<document-id>
<country>US</country>
<doc-number>20070003564</doc-number>
<kind>A1</kind>
<date>20070104</date>
</document-id>
</publication-reference>
<application-reference appl-type="utility">
<document-id>
<country>US</country>
<doc-number>11473941</doc-number>
<date>20060623</date>
</document-id>
</application-reference>
<us-application-series-code>11</us-application-series-code>
<classifications-ipcr>
<classification-ipcr>
<ipc-version-indicator><date>20060101</date></ipc-version-indicator>
<classification-level>A</classification-level>
<section>A</section>
<class>61</class>
<subclass>K</subclass>
<main-group>39</main-group>
<subgroup>00</subgroup>
<symbol-position>F</symbol-position>
<classification-value>I</classification-value>
<action-date><date>20070104</date></action-date>
<generating-office><country>US</country></generating-office>
<classification-status>B</classification-status>
<classification-data-source>H</classification-data-source>
</classification-ipcr>
<classification-ipcr>
<ipc-version-indicator><date>20060101</date></ipc-version-indicator>
<classification-level>A</classification-level>
<section>A</section>
<class>61</class>
<subclass>K</subclass>
<main-group>38</main-group>
<subgroup>17</subgroup>
<symbol-position>L</symbol-position>
<classification-value>I</classification-value>
<action-date><date>20070104</date></action-date>
<generating-office><country>US</country></generating-office>
<classification-status>B</classification-status>
<classification-data-source>H</classification-data-source>
</classification-ipcr>
<classification-ipcr>
<ipc-version-indicator><date>20060101</date></ipc-version-indicator>
<classification-level>A</classification-level>
<section>A</section>
<class>61</class>
<subclass>K</subclass>
<main-group>31</main-group>
<subgroup>7012</subgroup>
<symbol-position>L</symbol-position>
<classification-value>I</classification-value>
<action-date><date>20070104</date></action-date>
<generating-office><country>US</country></generating-office>
<classification-status>B</classification-status>
<classification-data-source>H</classification-data-source>
</classification-ipcr>
<classification-ipcr>
<ipc-version-indicator><date>20060101</date></ipc-version-indicator>
<classification-level>A</classification-level>
<section>A</section>
<class>61</class>
<subclass>K</subclass>
<main-group>31</main-group>
<subgroup>045</subgroup>
<symbol-position>L</symbol-position>
<classification-value>I</classification-value>
<action-date><date>20070104</date></action-date>
<generating-office><country>US</country></generating-office>
<classification-status>B</classification-status>
<classification-data-source>H</classification-data-source>
</classification-ipcr>
</classifications-ipcr>
<classification-national>
<country>US</country>
<main-classification>424184100</main-classification>
<further-classification>514002000</further-classification>
<further-classification>514053000</further-classification>
<further-classification>514738000</further-classification>
</classification-national>
<invention-title id="d0e279">Diluent for immunohistochemistry</invention-title>
<us-related-documents>
<us-provisional-application>
<document-id>
<country>US</country>
<doc-number>60696026</doc-number>
<date>20050630</date>
</document-id>
</us-provisional-application>
</us-related-documents>
<parties>
<applicants>
<applicant sequence="00" app-type="applicant-inventor" designation="us-only">
<addressbook>
<last-name>Hurley</last-name>
<first-name>John</first-name>
<middle-name>K.</middle-name>
<address>
<city>Tucson</city>
<state>AZ</state>
<country>US</country>
</address>
</addressbook>
<nationality>
<country>US</country>
</nationality>
<residence>
<country>US</country>
</residence>
</applicant>
<applicant sequence="01" app-type="applicant-inventor" designation="us-only">
<addressbook>
<last-name>Hartman</last-name>
<first-name>Anthony</first-name>
<middle-name>L.</middle-name>
<address>
<city>Tucson</city>
<state>AZ</state>
<country>US</country>
</address>
</addressbook>
<nationality>
<country>US</country>
</nationality>
<residence>
<country>US</country>
</residence>
</applicant>
</applicants>
<correspondence-address>
<addressbook>
<name>VENTANA MEDICAL SYSTEMS, INC.;ATTENTION: LEGAL DEPARTMENT</name>
<address>
<address-1>1910 INNOVATION PARK DRIVE</address-1>
<city>TUCSON</city>
<state>AZ</state>
<postcode>85755</postcode>
<country>US</country>
</address>
</addressbook>
</correspondence-address>
</parties>
</us-bibliographic-data-application>
<abstract id="abstract">
<p id="p-0001" num="0000">An embodiment of the invention is directed to a method and diluent for stabilizing biomolecules, comprising Tris and a polyhydroxy carbohydrate selected from the group consisting of mannitol and trehalose. The diluent may optionally include casein added as a background blocking protein. The diluent may optionally include sodium azide as an anti-microbial agent. Mannitol and/or trehalose are particularly useful embodiments of polyhydroxy carbohydrates. </p>
</abstract>
<drawings id="DRAWINGS">
<figure id="figure-D00001" num="00001">
<img id="EMI-D00001" he="189.23mm" wi="151.55mm" file="US20070003564A1-20070104-D00001.TIF" alt="embedded image" img-content="drawing" img-format="tif"/>
</figure>
<figure id="figure-D00002" num="00002">
<img id="EMI-D00002" he="202.35mm" wi="141.22mm" file="US20070003564A1-20070104-D00002.TIF" alt="embedded image" img-content="drawing" img-format="tif"/>
</figure>
<figure id="figure-D00003" num="00003">
<img id="EMI-D00003" he="175.34mm" wi="138.68mm" file="US20070003564A1-20070104-D00003.TIF" alt="embedded image" img-content="drawing" img-format="tif"/>
</figure>
<figure id="figure-D00004" num="00004">
<img id="EMI-D00004" he="180.09mm" wi="173.14mm" file="US20070003564A1-20070104-D00004.TIF" alt="embedded image" img-content="drawing" img-format="tif"/>
</figure>
<figure id="figure-D00005" num="00005">
<img id="EMI-D00005" he="181.61mm" wi="174.92mm" file="US20070003564A1-20070104-D00005.TIF" alt="embedded image" img-content="drawing" img-format="tif"/>
</figure>
</drawings>
<description id="description">
<?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="lead"?>
<heading level="2" id="h-0001">CROSS-REFERENCE TO RELATED CASES </heading>
<p id="p-0002" num="0001"> This application claims priority to U.S. Provisional patent application Ser. No. 60/696,026 filed 06/30/2005, the entire contents of which are incorporated by reference herein.</p>
<?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="tail"?>
<?summary-of-invention description="Summary of Invention" end="lead"?>
<heading level="2" id="h-0002">BACKGROUND </heading>
<p id="p-0003" num="0002"> 1. Field of the Invention </p>
<p id="p-0004" num="0003"> The invention relates generally to the field of life sciences, more particularly the field of preservation and storage of proteins, and further to the field of stabilizing biomolecules for subsequent shipping and storage for later use in Immunohistochemistry (&#x201c;IHC&#x201d;). </p>
<p id="p-0005" num="0004"> 2. Description of Related Art </p>
<p id="p-0006" num="0005"> Buffered protein solutions have long been used as diluents, or stabilizing buffered solutions, for storage and dilution of active biomolecules such as for example antibodies. Diluents also serve the function of reducing non-specific binding to containers they are in, and to tissue components they may later contact in normal analytical use. Sugars such as Sorbitol (Andersson, Maria, <i>Protein Stabilization. Some Methods and Mechanisms, </i>Dissertation abstract, Lund University, 1999, http://theses.lub.lu.se/postgrad/) have been used historically to improve the stability of proteins during and after the lyophilization process (essentially freeze-drying) to improve their shelf-life. Lyophilized antibodies generally have much longer shelf-lives, and in some cases may be stored indefinitely if kept in a low-temperature environment. However, antibodies stored in diluents still do not match the shelf life of a lyophilized antibody, so improved diluents are still needed. </p>
<p id="p-0007" num="0006"> Numerous publications in the art disclose means of increasing the stability of a lyophilized reagent, and the difficulties inherent even within this state-of-the-art technology. For example, U.S. Pat. Nos. 5,955,448, 4,496,537, and PCT filing WO 97/04801 all disclose improvements in lyophilization techniques. Lyophilization of protein-containing solutions, however, imposes major costs and inconvenience on the manufacturer and the end user, as well as introducing an increased risk of reconstitution errors and contamination. Additionally, freeze-drying of a solution requires special equipment and ultimately can lead to protein degradation when repeated cycling occurs. For commercial use, deterioration of polypeptides and antigens in aqueous solutions is costly because such solutions require replacement after only a short storage life. </p>
<p id="p-0008" num="0007"> PCT pub. No. WO99/15901 discloses a diluent for the stabilization of antigens, in particular, Hepatitis C Virus (HCV) antigens. The HCV diluent comprises a reducing agent to keep the HCV antigens in a reduced form. The publication reports that the inclusion of a reducing agent in a diluent maintained the immunoreactivity of an HCV antigen for up to seven days. The reported diluent further comprises sodium phosphate, pH 6.5 (or other buffer), EDTA (or other chelator), DTT (or other reducing agent), gelatin (or other protein blocking source), ammonium thiocyanate (or other chaotrope), sodium azide (or other preservative) and SDS (or other detergent). </p>
<p id="p-0009" num="0008"> U.S. Pat. No. 4,956,274 concerns techniques for stabilizing peptide fragments from beta-galactosidase for use in complementation assays. The solution disclosed in U.S. Pat. No. 4,956,274 contained an ionic surfactant or a surfactant derived from a sugar residue to slow degradation of beta-galactosidase peptide fragments. However, the surfactants also denatured the enzyme fragments, and thus had to be removed or neutralized to enable the enzymatic fragments to return to their correct conformation and regain enzymatic activity, indicating that the solution did not stabilize the native form of the protein. The surfactants are neutralized just prior to the assay by using cyclodextrin. Alternatively, the action of the surfactants was masked with a high concentration of serum. Additional components of the disclosed reagent included a chelating agent, buffer, bacteriocide, magnesium or other ions, reducing agents, solubilizing agents such as solvents like ethylene glycol, and nonionic detergents. As those in the art will appreciate denaturing and renaturing proteins or enzyme fragments may damage some antigenic epitopes and render them inactive. </p>
<p id="p-0010" num="0009"> Landi, S. and Held, H. R. (Tubercle 59 (1978) 121-133) reported the addition of TWEEN&#x2122; 20 (Polyoxyethylene Sorbitan Monooleate), detergent into a diluted solution and suggested that tuberculin PPD stability was enhanced by this addition due to the detergent's anti-adsorptive properties. The tuberculin preparation, made by Connaught Laboratories, LTD., contains tuberculin PPD, 0.3% phenol (reported to act as a preservative), and 0.0005% TWEEN&#x2122; 80 (Polyoxyethylene Sorbitan Monooleate) in PBS. </p>
<p id="p-0011" num="0010"> U.S. Pat. No. 6,579,688 (Steaffen et al.) discloses a diluent useful for stabilizing antigens useful in analytical procedures comprising 50 mM sodium phosphate, 2% v/v fetal calf serum, 1% v/v glycerol, 50 mM sodium chloride, 5 mM EDTA, 0.05% v/v TWEEN 20 (Polyoxyethylene Sorbitan Monolaurate) detergent, 0.01% w/v quaternary ammonium compound, and 0.5% w/v gentamycin sulfate. </p>
<heading level="2" id="h-0003">SUMMARY OF THE INVENTION </heading>
<p id="p-0012" num="0011"> An embodiment of the invention is directed to a diluent for stabilizing biomolecules, comprising Tris and a polyhydroxy carbohydrate selected from the group consisting of mannitol and trehalose. The diluent may optionally include casein added as a background blocking protein. The diluent may optionally include sodium azide as an anti-microbial agent. Mannitol and/or trehalose are particularly useful embodiments of polyhydroxy carbohydrates. Another embodiment of the invention is a method for stabilizing biomolecules comprising storing a biomolecule in a diluent comprising Tris and a polyhydroxy carbohydrate selected from the group consisting of mannitol and trehalose.</p>
<?summary-of-invention description="Summary of Invention" end="tail"?>
<?brief-description-of-drawings description="Brief Description of Drawings" end="lead"?>
<heading level="2" id="h-0004">BRIEF DESCRIPTION OF THE DRAWINGS </heading>
<p id="p-0013" num="0012"> <figref idref="DRAWINGS">FIG. 1</figref> shows four microphotographs of tonsil sections stained with anti-Ki67 antibody using QDot 605-Streptavidin conjugate on Day 0 and Day 1 following one day of storage at 37 degrees C. MDS diluent is used on the left frames, while casein+0.08% NaN3 is used in the two frames on the right. </p>
<p id="p-0014" num="0013"> <figref idref="DRAWINGS">FIG. 2</figref> shows four photomicrographs of anti-CD45 LCA staining of tonsil sections detected using a Qdot 605-Streptavidin conjugate. Comparison of Casein (15 mg/ml, 0.08% NaN3) with Tris buffered manitol containing bovine serum albumin, bovine gamma globulin or casein. </p>
<p id="p-0015" num="0014"> <figref idref="DRAWINGS">FIG. 3</figref> shows four photomicrographs of anti-CD45 LCA staining of tonsil sections detected using a Qdot 605-streptavidin conjugate. Comparison of Casein (15 mg/ml, 0.08% NaN3) with Tris buffered manitol containing bovine serum albumin, bovine gamma globulin or casein. </p>
<p id="p-0016" num="0015"> <figref idref="DRAWINGS">FIG. 4</figref> shows six Tonsil sections stained with anti-CD45 LCA diluted in either MDS antibody diluent or 50 mM Tris, 100 mM Manitol, 2 mg/ml Casein and 0.08% NaN3 and stored at 45&#xb0; C. </p>
<p id="p-0017" num="0016"> <figref idref="DRAWINGS">FIG. 5</figref> shows six photomicrographs of carcinoma sections stained with anti-pERK antibody diluted in either TBST antibody diluent or 50 mM Tris, 100 mM Mannitol, 2 mg/ml Casein and 0.08% NaN3 and stored at 45&#xb0; C.</p>
<?brief-description-of-drawings description="Brief Description of Drawings" end="tail"?>
<?detailed-description description="Detailed Description" end="lead"?>
<heading level="2" id="h-0005">DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS </heading>
<p id="p-0018" num="0017"> The diluent of the present invention comprises a Tris buffer, and a polyhydroxy carbohydrate selected from the group consisting of Mannitol and trehalose. Casein may be useful as a background blocker for subsequent staining runs. Optionally, a preservative anti-microbial such as sodium azide may be used. The preferred diluent is Tris (pH 7.2), mannitol, hydrolyzed casein and sodium azide. The diluent may be used to dilute antibodies or other biomolecules for shipment and/or storage. </p>
<p id="p-0019" num="0018"> Trizma&#xae; base (Tris(hydroxymethyl)aminomethane) is the preferred buffer for this diluent. It is available from many suppliers but one is Sigma-Aldrich (St. Louis, Mo.) P/N T6066. Although it may be useful in a range of concentrations, it is most preferred at 0.05 molar (50 mmol), and physiological pH (pH 6.8-7.8). pH 7.2 is preferred. pH is adjusted simply by adding concentrated HCl until the desired pH is attained. </p>
<p id="p-0020" num="0019"> A polyhydroxy carbohydrate is an organic compound consisting of a chain of carbon atoms to which hydrogen and oxygen are attached in a 2:1 ratio, eg, sugars, starch, glycogen, cellulose, and that contain multiple hydroxy (&#x2014;OH) groups. </p>
<p id="p-0021" num="0020"> D-Mannitol is a sugar alcohol, available from Sigma-Aldrich, P/N M9647. The concentration range is from about 100 to about 400 mmol, and most preferred is 100 mmol. Trehalose is a naturally occurring disacharride composed of two D-glucopyranose units. It was recently reported by Lins et al, Lins, Roberto D., <i>PROTEINS: Structure, Function and Bioinformatics </i><b>55:177-186 </b>(2004), as a protein stabilizer. It is also available from Sigma-Aldrich, P/N T9531 (dihydrate form). </p>
<p id="p-0022" num="0021"> An anti-microbial agent is optionally included. One which has been found to not interfere with IHC requirements is sodium azide. It is available from many suppliers, including Sigma, P/N S-2002. The least amount appropriate to retard microbial growth was used since it is generally toxic, and can be explosive under certain circumstances. 0.05 wt./vol. % 0.1% is a generally preferred range, and 0.08% is a preferred concentration used herein. </p>
<p id="p-0023" num="0022"> A background blocking agent is generally used with antibody diluents so that non-specific protein-protein binding is minimized in subsequent staining runs. Non-specific protein-protein binding may occur between the primary antibody and many other proteins in the tissue sample, so some method of quenching this &#x201c;stickiness&#x201d; should be used to inhibit background signal. Many proteins can be used for this, including Bovine Serum Albumin (BSA), Bovine Gamma Globulin (BGG) and hydrolyzed casein. Particularly preferred is hydrolyzed casein from American Casein Co. (Burlington, N.J.), P/N HCA-411. Concentrations of from 2 mg/ml to 15 mg/ml are useful, although 2 mg/ml is preferred. One of ordinary skill in the histology art will know of many interchangeable blocking proteins that can be utilized. Individual blocking buffers are not compatible with every system. For this reason, a variety of blockers in both Tris buffered saline (TBS) and phosphate buffered saline (PBS) are available. The proper choice of blocker for a given tissue depends on the antigen itself and on the type of enzyme conjugate to be used. For example, with applications using an alkaline phosphatase conjugate, a blocking buffer in TBS should be selected, because PBS interferes with alkaline phosphatase. The ideal blocking buffer will bind to all potential sites of nonspecific interaction, eliminating background altogether without altering or obscuring the epitope for antibody binding. For true optimization of the blocking step for a particular immunohistochemical assay, empirical testing is essential. Many factors, including various protein:protein interactions unique to a given set of immunoassay reagents, can influence nonspecific binding. The most important parameter when selecting a blocker is the signal:noise ratio, measured as the signal obtained with a tissue sample containing the target analyte, as compared to that obtained with a sample without the target analyte. Using inadequate amounts of blocker will result in excessive background staining and a reduced signal:noise ratio. Using excessive concentrations of blocker may mask antibody:antigen interactions or inhibit the marker enzyme, again causing a reduction of the signal:noise ratio. When developing any new immunoassay, it is important to test several different blockers for the highest signal:noise ratio in the assay. No single blocking agent is ideal for every occasion since each antibody-antigen pair has unique characteristics. Agents such as nonfat dry milk and salmon serum, in addition to those mentioned above, may be used. </p>
<p id="p-0024" num="0023"> Formulation 1 is 50 mmol Trizmag HCl, 100 mmol mannitol, 2 mg/ml hydrolyzed casein and sodium azide 0.08%. This formulation was used in the examples below to dilute the antibodies mentioned. It is referred to as the &#x201c;TBMC&#x201d; diluent. Prior art diluent MDS is 77 mM Sodium Phosphate, dibasic; 23 mM Sodium Phosphate, monobasic; 54.75 mM Sodium Chloride; 0.05% Brij 35; 15.0 mg/ml Hydrolyzed Casein Protein; 0.05% ProClin 300. TBST diluent is 19.98 mM Trizma&#xae; Base; 136.89 mM Sodium Chloride; 0.1% Tween 20; 5% Normal Goat Serum (Chemicon International, Temecula, Calif., P/N S26). </p>
<heading level="2" id="h-0006">EXAMPLES </heading>
<heading level="2" id="h-0007">Example 1 </heading>
<heading level="2" id="h-0008">LCA, pERK &#xbd; Antibody Stability </heading>
<p id="p-0025" num="0024"> The stabilities of two antibodies, anti-pERK &#xbd; and LCA, were compared to their stability in the novel TBMC diluent, and the prior art MDS and TBST diluents, at the elevated temperature of 45&#xb0; C., a standard ship-stress test temperature. Anti-CD45 Leucocyte Common Antigen (LCA) clone 2B11 from Neomarkers, Inc., Fremont, Calif., P/N MS-1884-P0 was used. 4 &#x3bc;m tonsil sections were prepared for staining on a DISCOVERY&#xae; automated tissue stainer (Ventana). </p>
<p id="p-0026" num="0025"> The present MDS diluent is hostile to the stability of phosphorylated antibodies, as seen in <figref idref="DRAWINGS">FIG. 4</figref> in the top three frames labeled &#x201c;MDS Diluent Day X&#x201d;, where X is 0 in the first frame, and increases with increasing time in the diluent to 14 days in the last frame. By the last frame (Day 14) all antibody activity is gone in the MDS diluent, whereas in the TBMC diluent the LCA antibody is still staining the tonsil sections well. </p>
<p id="p-0027" num="0026"> We then looked at the stability of phospho-ERK&#xbd; (&#x201c;pERK&#x201d;) from Biosource International, Camarillo, Calif., P/N 44-680G in the TBMC diluent and in TBST diluent. </p>
<p id="p-0028" num="0027"> In <figref idref="DRAWINGS">FIG. 5</figref>, the top three frames show the pERK antibody diluted in TBMC diluent, and in TBST diluent (bottom three frames) at time=0, 7 days, and 14 days. Stability in both diluents is apparent. The sections stained were 4 um breast carcinoma sections sourced from the in-house Ventana tissue bank. However, those of ordinary skill will appreciate that any breast carcinoma tissue expresses pERK, and so any breast tumor tissue may be used. </p>
<heading level="2" id="h-0009">Example 2 </heading>
<heading level="2" id="h-0010">Stability of Quantum Dot Conjugates </heading>
<p id="p-0029" num="0028"> &#x201c;Quantum Dots&#x201d; are semiconductor nanocrystal-based fluorescent tags that are being used in life sciences research due to their ability to emit narrow frequencies of light when appropriately excited. They can be conjugated to biomolecules such as haptens, antibodies or DNA probes, and then bound or hybridized to their respective biological targets. </p>
<p id="p-0030" num="0029"> <figref idref="DRAWINGS">FIG. 1</figref> shows the problems encountered with the prior art MDS diluent with the QDot&#xae;-Streptavidin conjugate when used to detect the primary antibody anti-Ki-67, clone K-2 (Ventana P/N 790-2910). 4 um tonsil sections were prepared for staining on a DISCOVERY system, as before. QDot 605 conjugated to Streptavidin (Invitrogen Corp., Carlsbad, Calif., P/N Q21301MP) was diluted into both the prior art MDS diluent, and a casein/Sodium azide diluent (2 ug/ml hydrolyzed casein; 0.08% NaN3). The two left frames show tonsil sections stained with the Ki67/QDot 605 combination diluted into the MDS diluent on Day 0. (top-left) and Day 1 (bottom left). The signal clearly declines rapidly to being non-existent on Day 1. By contrast, switching to a casein-only diluent reduces the fading of the QDot 605 signal greatly so that there is no apparent fading between Day 0 and Day 1. Clearly, the MDS diluent is not friendly to QDot conjugate stability at 37&#xb0; C. </p>
<p id="p-0031" num="0030"> <figref idref="DRAWINGS">FIG. 2</figref> shows the effect casein seems to have in the TBMC diluent. The figure shows a different antibody anti-CD45 antibody LCA being stained on tonsil sections, and then being detected using the same QDot-Streptavidin 605 conjugate. This figure shows that the blocking proteins behave surprisingly differently regarding stability of the diluent. For instance, the signals degrade most rapidly in BGG (bovine gamma globulin, bottom right), then degrade significantly in BSA (bovine serum albumin, top right) then not at all in casein (top left). These results were generated at 45&#xb0; C. </p>
<p id="p-0032" num="0031"> <figref idref="DRAWINGS">FIG. 3</figref> is a longer term (5 days versus two) and higher temperature (45 v. 37) test of the TBMC diluent discussed in <figref idref="DRAWINGS">FIG. 2</figref>. The results are similar, with increased degradation of signal over the extra time and higher temperatures in all diluents. </p>
<p id="p-0033" num="0032"> While the invention has been described with reference to an illustrative embodiment, it will be understood by those skilled in the art that various changes, omissions and/or additions may be made and equivalents may be substituted for elements thereof without departing from the spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation or material to the teachings of the invention without departing from the scope thereof. Therefore, it is intended that the invention not be limited to the particular embodiments disclosed as the best mode contemplated for carrying out this invention, but that the invention will include all embodiments falling within the scope of the appended claims. </p>
<?detailed-description description="Detailed Description" end="tail"?>
</description>
<us-claim-statement>We claim: </us-claim-statement>
<claims id="claims">
<claim id="CLM-00001" num="00001">
<claim-text><b>1</b>. A diluent for stabilizing biomolecules, comprising Tris and a polyhydroxy carbohydrate selected from the group consisting of mannitol and trehalose. </claim-text>
 </claim>
<claim id="CLM-00002" num="00002">
<claim-text><b>2</b>. The diluent of <claim-ref idref="CLM-00001">claim 1</claim-ref> wherein casein is optionally added as a background blocking protein. </claim-text>
 </claim>
<claim id="CLM-00003" num="00003">
<claim-text><b>3</b>. The diluent of <claim-ref idref="CLM-00001">claim 1</claim-ref> wherein the Tris concentration is effective to buffer the pH to between about 6.8 and about 7.8. </claim-text>
 </claim>
<claim id="CLM-00004" num="00004">
<claim-text><b>4</b>. The diluent of <claim-ref idref="CLM-00001">claim 1</claim-ref> wherein the concentration of the polyhydroxy carbohydrate ranges from about 100 to about 400 mmol. </claim-text>
 </claim>
<claim id="CLM-00005" num="00005">
<claim-text><b>5</b>. The diluent of <claim-ref idref="CLM-00002">claim 2</claim-ref> wherein the concentration of casein ranges from about 2 mg/ml to about 15 mg/ml. </claim-text>
 </claim>
<claim id="CLM-00006" num="00006">
<claim-text><b>6</b>. The diluent of <claim-ref idref="CLM-00001">claim 1</claim-ref> wherein optionally is included sodium azide, and the concentration of sodium azide ranges from about 0.05 to about 0.10%, wt./vol. </claim-text>
 </claim>
<claim id="CLM-00007" num="00007">
<claim-text><b>7</b>. The diluent of <claim-ref idref="CLM-00001">claim 1</claim-ref> wherein the Tris concentration is about 50 mM. </claim-text>
 </claim>
<claim id="CLM-00008" num="00008">
<claim-text><b>8</b>. The diluent of <claim-ref idref="CLM-00001">claim 1</claim-ref> wherein the mannitol concentration is about 100 mM. </claim-text>
 </claim>
<claim id="CLM-00009" num="00009">
<claim-text><b>9</b>. The diluent of <claim-ref idref="CLM-00002">claim 2</claim-ref> wherein the casein is about 2 mg/mi. </claim-text>
 </claim>
<claim id="CLM-00010" num="00010">
<claim-text><b>10</b>. The diluent of <claim-ref idref="CLM-00006">claim 6</claim-ref> wherein the sodium azide is about 0.08% wt./vol. </claim-text>
 </claim>
<claim id="CLM-00011" num="00011">
<claim-text><b>11</b>. A diluent for stabilizing biomolecules in aqueous solution, comprising 50 mmol Tris, 100 mmol mannitol, 2 mg/ml casein and sodium azide 0.08%. </claim-text>
 </claim>
<claim id="CLM-00012" num="00012">
<claim-text><b>12</b>. A method for stabilizing a biomolecule comprising storing a biomolecule in the diluent of <claim-ref idref="CLM-00001">claim 1.</claim-ref></claim-text>
 </claim>
</claims>
</us-patent-application>
